Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05239169
Title Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications

intrahepatic cholangiocarcinoma

biliary tract cancer

Klatskin's tumor

gallbladder carcinoma

extrahepatic bile duct carcinoma

Therapies

Capecitabine + Durvalumab + Tremelimumab

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.